financetom
Business
financetom
/
Business
/
Why Scinai Immunotherapeutics Stock Is Skyrocketing 90% Higher Today
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Why Scinai Immunotherapeutics Stock Is Skyrocketing 90% Higher Today
Apr 24, 2026 7:51 AM

Scinai Immunotherapeutics Ltd ( SCNI ) – ADR shares are surging Friday morning after the company announced fresh financing tied to a private placement and warrant exercise, helping refocus attention on its near-term funding runway. Here’s what investors need to know.

Scinai Immunotherapeutics ( SCNI ) stock is showing downward pressure. What’s the outlook for SCNI shares?

What Is Scinai’s $2.61 Million Financing Catalyst?

Scinai announced about $2.61 million in gross proceeds from a private placement financing plus a warrant inducement, with closing expected on or about April 27, 2026, subject to customary conditions.

The warrant inducement covers immediate exercise of up to 229,310 ADSs at 48 cents per ADS, paired with new unregistered warrants for up to 458,621 ADSs at 55 cents per ADS that expire five years from issuance.

The company said it plans to use net proceeds (alongside existing cash) to expand its CDMO platform, advance customer programs, and keep selectively investing in its immunotherapy pipeline.

SCNI Stock: Critical Levels To Watch

Scinai is trying to stabilize off its April swing low while still sitting far below its longer-term trend, which keeps the bigger-picture chart fragile. The stock is trading 43.7% above its 20-day simple moving average (SMA) and 3.6% above its 100-day SMA, which leans toward a short-term rebound that's only starting to test intermediate trend pressure.

The relative strength index (RSI), a momentum gauge, is 25.74, which is in oversold territory and lines up with the oversold signal that appeared in April. RSI at 25.74 reflects heavy recent selling pressure, even if bounces can show up quickly from these levels.

The 12-month return is -65.70%, which is consistent with a longer-term downtrend that hasn't been repaired yet. That longer-term damage also shows up in the moving-average structure, with the 50-day SMA still below the 200-day SMA (a bearish long-term alignment) and price still below the 200-day SMA.

Key Resistance: $1.00 — a round-number area that often caps early rebound attempts

Key Support: 50 cents — near the lower end of the recent trading zone

SCNI Stock Price Activity On Friday

SCNI Stock Price Activity: Scinai Immunotherapeutics ( SCNI ) shares are trading higher by 92.11% to 87 cents at the time of publication on Friday, according to Benzinga Pro data.

Read Also:

Stock Market Today: Nasdaq, S&P 500 Futures Gain While Dow Slips Amid Israel-Lebanon Ceasefire Extension—Intel, SAP, Lunai Bioworks In Focus

Image: Adobe Stock Images

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Nextracker Fiscal Q2 Adjusted Earnings, Revenue Rise; Shares Jump After Hours
Nextracker Fiscal Q2 Adjusted Earnings, Revenue Rise; Shares Jump After Hours
Oct 23, 2025
04:39 PM EDT, 10/23/2025 (MT Newswires) -- Nextracker ( NXT ) reported fiscal Q2 adjusted earnings late Thursday of $1.19 per diluted share, up from $0.97 a year earlier. Analysts polled by FactSet expected $1.01. Revenue in the three months ended Sept. 26 rose to $905.3 million from $635.6 million a year earlier. Analysts surveyed by FactSet expected $842.8 million....
Anthropic to use 1 million Google Cloud TPU chips to train its Claude chatbot
Anthropic to use 1 million Google Cloud TPU chips to train its Claude chatbot
Oct 23, 2025
(Reuters) -Anthropic said on Thursday it Claude models would be trained using up to one million of Google Cloud's tensor processing units, worth tens of billions of dollars. The deal underscores the immense computing demands of AI firms for training, deployment and continuous inference in generative AI, as they race to launch new products and features to stay ahead in...
Oregon Pacific Bancorp Q3 net income rises on deposit growth
Oregon Pacific Bancorp Q3 net income rises on deposit growth
Oct 23, 2025
Overview * Oregon Pacific Bancorp ( ORPB ) Q3 net income rises to $2.2 mln, $0.31 per share * Company's Q3 deposits grow by $28.7 mln, driven by terminating trust activity * Net interest margin for Q3 expands to 3.88%, up from 3.85% in prior quarter Outlook * Company expects $9 mln in trust-related deposits to leave in Q4 Result...
BayCom misses Q3 net income estimates on higher credit loss provisions
BayCom misses Q3 net income estimates on higher credit loss provisions
Oct 23, 2025
Overview * BayCom ( BCML ) Q3 net income of $5.0 mln misses analyst expectations * Net income decreased 21.3% from Q2 2025 due to higher credit loss provisions * Company repurchased 33,300 shares at $27.29 average cost in Q3 2025 Outlook * BayCom ( BCML ) expects stable credit quality and improving earnings performance despite economic uncertainties * Company...
Copyright 2023-2026 - www.financetom.com All Rights Reserved